Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of ...

US biotech Ultragenyx Pharmaceutical saw its shares tumble over 43% to $19.41 yesterday, after it announced results from the ...

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...

The clinical trial supply & logistics market grew from USD 26.20 billion in 2024 to USD 28.21 billion in 2025. It is expected to continue growing at a CAGR of 7.96%, reaching USD ...

Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of im ...

Pharmaceutical announced results from the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta. Neither ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improv ...